【Abstract】 Objective To research the impact of PPARα agonist on liver and kidney function and blood fat index in PPARα transgenic mouse, and to detect these indices in the model if they can be applied to the study of pharmacodynamics. Methods Twenty-seven mice, at the age of 6 weeks, were divided into three group(each n=9), and fed with high-fat forage for a mounth.They were control group one，high dose group(60 mg/kg of fenofibrate),low dose group(30 mg/kg of fenofibrate).At the same time, 9 C57BL/6 mice were set as the control group two. The time of gavage administration lasted one month. The liver function index, kidney function index ,and blood fat index were tested before and after the drug administration. The growth of the mice was also observed. Results ①The comparison after fenofibrate administration :Compared with control group one, in the PPARα transgenic mouse with the fenofibrate dosage of 60 mg/kg、30 mg/kg, the level of triglycerides (TG) was reduced markedly (P＜0.05）and the high-density lipoprotein cholesterol (HDL-C) 、CHO level was increased markedly (P＜0.05). However, there was no obvious statistics difference on weigh among all groups(P＞0.05) . ②The comparison before and after fenofibrate administration :Compared with the value before fenofibrate administration, the ALT、AST、ALP、BUN、TG were obviously reduced after the administration of 60 mg/kg fenofibrate (P＜0.05）,in addition, the CHO、HDL-C were obviously raised (P＜0.01）.However, in the 30 mg/kg fenofibrate administration group, ALP was obviously reduced (P＜0.05）,and the CHO、HDL-C were obviously raised (P＜0.05）.Conclusion Compared with C57BL/6 mouse ,the PPARα transgenic mouse has the sensibility in evaluation of PPARα agonist. It is a new animal model .